DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Merck - 3 Keytruda - 1
Top related locs:
U.S Rahway , New Jersey New York City , New York
Top related orgs:
Merck - 3 Harpoon Therapeutics - 3 LSEG - 3 Prometheus Biosciences - 1 Merck & Co - 1 New York Stock Exchange - 1

Search resuls for: "Harpoon Therapeutics"


3 mentions found


☆ Merck beats earnings expectations, raises sales outlook on strong demand for top drugs like Keytruda
  + stars: | 2024-07-30 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +2 min
Merck on Tuesday reported second-quarter revenue and adjusted earnings that topped Wall Street's expectations as it saw strong sales from its blockbuster cancer drug Keytruda as well as other treatments in its oncology and vaccines portfolios and a newly launched cardiovascular drug. The pharmaceutical giant also raised its full-year sales forecast to a range of $63.4 billion to $64.4 billion on increased demand for key products, particularly its oncology treatments. That's only slightly higher than the $63.1 billion to $64.3 billion guidance the company provided in April. Merck reported $16.11 billion in revenue for the quarter, up 7% from the same period a year ago. Some analysts expect that worldwide sales of Winrevair could reach $5 billion by 2030.
Persons: Keytruda, Merck Organizations: Merck, Harpoon Therapeutics, LSEG, Prometheus Biosciences Locations: Rahway , New Jersey, U.S
☆ Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales
  + stars: | 2024-04-25 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +2 min
Merck on Thursday reported first-quarter revenue and adjusted earnings that topped expectations as it posted strong sales of its blockbuster cancer drug Keytruda and vaccine products. The pharmaceutical giant also raised and narrowed its full-year revenue and adjusted earnings forecasts. Merck now expects 2024 sales to come in between $63.1 billion and $64.3 billion, up from previous guidance of $62.7 to $64.2 billion. That outlook includes a one-time charge of roughly 26 cents per share related to Merck's acquisition of Harpoon Therapeutics in January. Merck raked in $15.78 billion in revenue for the quarter, up 9% from the same period a year ago.
Persons: Merck Organizations: Merck, Harpoon Therapeutics, LSEG Locations: Rahway , New Jersey, U.S
☆ Merck results beat expectations as top drugs Keytruda, Gardasil post strong sales
  + stars: | 2024-02-01 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +3 min
Merck on Thursday reported fourth-quarter revenue and adjusted earnings that topped estimates as it saw strong demand for its blockbuster cancer drug Keytruda and HPV vaccine Gardasil. Excluding acquisition and restructuring costs, Merck earned 3 cents per share for the fourth quarter. Merck raked in $14.63 billion in revenue for the quarter, up 6% from the same period a year ago. Analysts surveyed by LSEG expected Merck to forecast full-year sales of $63.52 billion and adjusted earnings of $8.42 per share. Merck recorded charges of $190 million related to the program in the fourth quarter, which is excluded from its adjusted results.
Persons: Merck Organizations: Merck & Co, New York Stock Exchange, Merck, LSEG, Harpoon Therapeutics Locations: New York City , New York, U.S
0 next >>
Total: 3